Common questions about Инкруз Эллипта (FAQ)
Q: How quickly should I feel a difference after starting Инкруз Эллипта?
Studies examining the pharmacological action of the medicine indicate that the bronchodilating effect—the relaxation of the airways—is typically observed within 30 minutes following administration. This observation relates to the drug's intended action as a sustained maintenance treatment.
Q: What are the most commonly reported side effects for Инкруз Эллипта?
According to official product information, the most commonly reported side effects observed in clinical trials were headache and nasopharyngitis (a cold-like symptom). These are the effects most frequently reported in the clinical trial data used for the official product information.
Q: Can patients with heart conditions generally use Инкруз Эллипта?
Regulatory documents advise that this class of medication, called muscarinic receptor antagonists, may cause certain cardiovascular effects, such as tachycardia (a fast heart rate) and atrial fibrillation. Official sources advise caution for use of this medicine in patients with pre-existing severe cardiovascular disorders, particularly cardiac arrhythmias.
Q: Is there a risk of developing glaucoma when using Инкруз Эллипта?
Due to its anticholinergic activity, official documents advise that this medicine should be used with caution in individuals with narrow-angle glaucoma. The regulatory warnings note a risk of new onset or worsening of acute narrow-angle glaucoma associated with this drug’s use.
Q: Does Инкруз Эллипта interact with common cold or flu medications?
Official documents do not list formal interaction studies with common over-the-counter cold or flu medicines. However, co-administration with any other medicine containing an anticholinergic agent is advised to be avoided because of the potential for additive effects.
Q: Can I use other inhalers at the same time as Инкруз Эллипта?
Clinical experience describes that this medicine has been used with other inhaled COPD medicines, including inhaled corticosteroids and short- or long-acting sympathomimetic bronchodilators, without clinical evidence of interactions. The main restriction is that co-administration with other anticholinergic-containing medicines is advised to be avoided.
Q: What is the main difference between an LAMA and an LABA medication?
These are different classes of bronchodilators used in COPD. A LAMA (Long-Acting Muscarinic Antagonist), like this drug, works by blocking specific receptors that cause airway muscles to tighten. An LABA (Long-Acting Beta Agonist) works by stimulating different receptors to relax those same airway muscles. Both actions result in sustained opening of the air passages.
Q: What is the difference between Инкруз Эллипта and Anoro Ellipta?
Инкруз Эллипта is a single-agent medicine that contains only umeclidinium, which is classified as a LAMA. Anoro Ellipta is a combination product that contains umeclidinium (LAMA) along with a second active ingredient, vilanterol, which is classified as an LABA (Long-Acting Beta Agonist).
--,-
Q: What is the longest period someone can use Инкруз Эллипта?
The medicine is indicated for long-term maintenance treatment of COPD. Clinical studies monitored patients for effects and safety for periods up to 52 weeks (one year).
Q: Is it normal to have a dry mouth when using Инкруз Эллипта?
Dry mouth is listed in the official product information as an uncommon adverse reaction, meaning that while it is not experienced by most people, it was reported in up to 1 in 100 people in clinical trials. It is a documented effect of this medication, which belongs to the anticholinergic class.
Q: Do studies suggest Инкруз Эллипта is effective for long-term use?
Clinical trials monitored patients for effectiveness over periods up to one year (52 weeks). Findings from these studies demonstrated that the improvement in lung function and bronchodilator effect was sustained over the examined period, with no attenuation observed.
Q: Can I take ibuprofen or Tylenol while using Инкруз Эллипта?
Official documents do not specifically list interactions with non-prescription pain relievers like ibuprofen or Tylenol (acetaminophen). The primary interaction concern is focused on avoiding other anticholinergic-containing medicines.
Q: Is there an age limit for starting treatment with Инкруз Эллипта?
Yes, this medicine is formally indicated for use only in adults, defined as individuals 18 years of age and older. It is not recommended for use in pediatric patients.
Q: Can pregnant or breastfeeding women use Инкруз Эллипта?
For pregnancy, use is conditional: it is permitted only if the expected benefit justifies the potential risk. For lactation, regulatory guidelines state that a decision must be made to either discontinue the medicine or discontinue breastfeeding, as it is unknown if the substance is excreted in human milk.
Q: What research has been done on the long-term safety of Инкруз Эллипта?
Long-term safety was monitored throughout the primary clinical trials for up to one year (52 weeks). Regulatory requirements also mandate ongoing post-authorisation safety studies, which continue to monitor patient outcomes, including selected cardiovascular and cerebrovascular events.
Q: What does 'maintenance treatment for COPD' mean for this drug?
Maintenance treatment means the drug is intended for long-term, continuous, once-daily use to help keep the airways open and prevent symptoms from occurring. It is not designed or intended to be used for the immediate or quick relief of sudden breathing problems.
Q: Is there any research on its use in severe kidney disease patients?
Clinical data available from studies indicate that no dose adjustment is required for patients with any degree of renal (kidney) impairment. This indicates that no dosage adjustment is required for patients with kidney impairment.
Q: What are the restrictions on using Инкруз Эллипта if I have urinary retention issues?
Due to its anticholinergic effects, official regulatory documents state that this medicine should be used with caution in patients who have a predisposition to urinary retention. Serious cases of worsening urinary retention have been reported with this class of medication.
Q: How long does the effect of one dose of Инкруз Эллипта last?
The way the active component works involves a slow rate of dissociation from the receptors in the airways. This results in a sustained blockade, meaning that the therapeutic effect of bronchodilation typically lasts for 24 hours.
Q: Is the sensation of not tasting or feeling the dose normal?
Yes, this is considered normal. The Ellipta device is designed to deliver a very fine dry powder dose directly to the lungs. If the inhalation technique is correct, it is common that the patient may not taste or feel the dose being inhaled.
Q: Does Инкруз Эллипта lose potency if the device is not used daily?
The drug’s stability is tied to its in-use shelf-life after opening the foil tray, not its daily use pattern. Once the foil tray is opened, the medicine has a fixed 'in-use' shelf-life of 6 weeks. It must be discarded after this time or when the dose counter reaches zero.
Q: Can this medication affect blood pressure or heart rate?
Yes, official safety documents list the potential for cardiovascular adverse events. These documented effects include hypertension (high blood pressure) and several types of irregular or fast heart rate, such as tachycardia, sinus tachycardia, and atrial fibrillation.
Q: Does the medicine contain lactose or other common allergens?
The medicine is a dry powder formulation and uses lactose monohydrate as an excipient (a non-active ingredient). Because of this, it is formally contraindicated (prohibited) for patients with a known severe hypersensitivity or allergy to milk proteins.
Q: Are there specific patient groups where the medicine is used with caution?
Official documents advise that caution is necessary when the medicine is used in individuals with pre-existing conditions such as narrow-angle glaucoma, urinary retention, and severe hepatic (liver) impairment.
Q: Is there a specific time of day recommended for taking Инкруз Эллипта?
The recommended use is once daily. Regulatory guidelines state that the dose should be inhaled at the same time each day to help maintain the continuous 24-hour bronchodilation effect.
Q: Does Инкруз Эллипта contain corticosteroids?
No, the active ingredient in this medicine is umeclidinium, which is classified as a Long-Acting Muscarinic Antagonist (LAMA). It is a bronchodilator and does not contain any corticosteroids (steroids).
Q: Is it common for studies to examine quality of life improvements with Инкруз Эллипта?
Yes, clinical trials routinely use specific Patient-Reported Outcomes (PROs), such as the St George's Respiratory Questionnaire (SGRQ). These standardized tools are used to objectively examine and report changes in a patient's health-related quality of life.
